Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KCTD21 antisense RNA 1 (KCTD21-AS1)
- Target
- KCTD21-AS1
- Molecular classification
- Long noncoding RNA (lncRNA), Antisense RNA
01
Overview
KCTD21 antisense RNA 1 (KCTD21-AS1) is a long noncoding RNA (lncRNA) transcribed from the antisense strand of the KCTD21 gene locus on chromosome 11. It is classified as an antisense RNA, primarily involved in the regulation of KCTD21 gene expression, likely through epigenetic and transcriptional mechanisms that can act in cis or trans[1][7][4][10]. KCTD21-AS1 has been observed to be differentially expressed in certain cancers and may modulate gene expression related to processes such as phagocytosis and autophagy within the tumor microenvironment[10][9]. To date, KCTD21-AS1 has not been established as a direct therapeutic target, receptor, or enzyme, and no drugs are known to interact with it specifically. Current research suggests its main biological significance is as a regulatory RNA molecule affecting gene expression within specific cellular contexts[1][4][7][3][10].
- Other names
- KCTD21-AS1ENSG0000024617411q14.1
02
Mechanism of action
Antisense-mediated regulation (cis/trans effects on KCTD21 gene expression); Epigenetic modulation by acting as enhancer RNA or recruiting transcription factors
03
Biological functions
Regulation of gene expression (specifically regulation of KCTD21 gene)Modulation of chromatin and transcriptional activityPotential regulation of cell signaling pathways (by regulating the expression of neighboring gene/protein targets)
04
Disease associations
Cancer (differential expression reported in certain cancers; modulates macrophage phagocytosis and autophagy relevant to tumor microenvironment)Other (current evidence for clinical/disease roles is limited and preliminary)
05
Safety considerations
Therapeutic modulation not established; no known safety concerns due to lack of drug interventions targeting this lncRNA
06
Biomarkers
May serve as a biomarker in cancer (expression correlates with cancer-related phenotypes, e.g., macrophage phagocytosis, autophagy)
Beyond the preview
Go deeper on KCTD21 antisense RNA 1 (KCTD21-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KCTD21 antisense RNA 1 (KCTD21-AS1).